🇺🇸 FDA
Patent

US 8715751

Artemisinins in the clinical and veterinary management of kinetoplastid infections

granted A61KA61K31/357A61K31/366

Quick answer

US patent 8715751 (Artemisinins in the clinical and veterinary management of kinetoplastid infections) held by The United States of America as represented by the Secretary of the Army expires Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army
Grant date
Tue May 06 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/357, A61K31/366, A61K36/282, A61P